Similarly, in a phase II trial of vandetanib (formerly ZD6474), a small molecule receptor tyrosine kinase inhibitor of both VEGFR and epidermal growth factor receptor (EGFR), no responses were found among 18 patients with relapsed MM [64]. The gene discussed is NTRK1; the disease is Miyoshi myopathy.